We give new life and purpose to anagrelide with targeted sarcoma therapy.
Sartar Therapeutics is developing a new precision medicine product, SAR001, to treat sarcomas. SAR001 specifically targets phosphodiesterase 3 protein -expressing tumors. SAR001 is based on drug reformulation and repositioning of anagrelide, previously approved for thrombocythaemia. SAR001 has a slow-release profile that shows superior pharmacokinetic properties over oral administration, making it better tolerated and more convenient for use in therapy.